<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>TUXUMDONLAR POLIKISTOZI SINDROMINING IMMUNOLOGIK MEXANIZMLARI: ANTIOVARIAL ANTITELALAR VA SURUNKALI YALLIG‘LANISHNING PATOGENEZ VA DAVOLASHDAGI ROLI</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">GULNARA</mods:namePart><mods:namePart type="family">MATRIZAYEVA</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">GULZODA</mods:namePart><mods:namePart type="family">RAJABOVA</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Ushbu tizimli sharh tuxumdonlar polikistozi sindromining (TPS) shakllanishida immun tizimi disregulyatsiyasining rolini tahlil qiladi. Tadqiqotda surunkali past darajali yallig‘lanish (low-grade inflammation), yallig‘lanishga moyil sitokinlar (IL-6, TNF-α) va antiovarial antitelalarning (AOA) tuxumdonlar disfunksiyasidagi o‘rni yoritilgan. Oxirgi 5 yillik (2021–2026 yy.) ilmiy manbalar tahlili shuni ko‘rsatadiki, TPS nafaqat endokrin, balki murakkab autoimmun komponentga ega tizimli patologiyadir. Maqolada ushbu mexanizmlarning bepushtlik bilan bog‘liqligi va yangi terapevtik yondashuvlar (immunomodulyatsiya) ko‘rib chiqilgan.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2026-04-13</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>South Aral Region Medical Journal</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>